RG7314

RG7314

RG7314 is a selective small molecule antagonist of the vasopressin V1A receptor which is under development by Roche for the treatment of autism.[1] As of August 2014, it is in phase II clinical trials for this indication.[2]

See also

References

External links



This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.